Vyome Holdings Publishes Preclinical Data for VT-1908
Vyome Holdings announced the publication of its preclinical data validating the efficacy and safety of VT-1908 as a potential treatment for uveitis in the peer-reviewed Journal of Ophthalmic Inflammation and Infection, a Springer-Nature journal. Uveitis refers to the immune-inflammation of the eye, and accounts for 10%-15% of all cases of blindness in the developed world. In the United States alone, it is associated with an estimated 30,000 new cases of legal blindness annually, and represents an estimated $3B market opportunity by 2032. In this publication, topical eye drops of VT-1908 resulted in the desired concentration of the active drug being achieved in the eye without any irritation or signs of toxicity. VT-1908-treated eyes showed a significant reduction in the uveitis score with reduced lymphocyte counts in the anterior chamber compared to vehicle control. VT-1908 was found to be as effective as topical prednisone in the preclinical model.
